tesamorelin ipamorelin stack benefits risks Tesamorelin and Ipamorelin:Combined Growth Hormone Therapy tesamorelin ipamorelin stack dosage SERMORELIN/IPAMORELIN

Ipamorelin + CJC-1295 Stack: Evidence, Mechanism, and Protocol At a glance Drug class / Growth hormone secretagogue (GHRP) + Growth hormone-releasing hormone analogue (GHRH analogue) Ipamorelin receptor target / Ghrelin receptor (GHSR-1a), selective, no cortisol or prolactin spike CJC-1295 receptor target / GHRH receptor (GHRHR) on pituitary somatotrophs Combination mechanism / GHRP + GHRH co-stimulation raises GH pulse amplitude 2-to-10-fold over either agent alone in animal models Typical ipamorelin dose / 100-300 mcg subcutaneous injection, 1-3x daily Typical CJC-1295 (no DAC) dose / 100-300 mcg subcutaneous injection, timed with ipamorelin Typical CJC-1295 with DAC dose / 1,000-2,000 mcg subcutaneous injection, once weekly Primary evidence level / Mechanistic + animal + one Phase II RCT (CJC-1295)

Many patients naturally reduce carbohydrate intake and increase protein consumption while on the medication

When reconstituted with bacteriostatic water and stored properly in a refrigerator (2-8C), IGF-1 LR3 remains stable and sterile for up to 28 days

As some Ipamorelin side effects bruising can occur, particularly if the injection technique is not precise

Medications are used to specifically treat symptoms of FASDs and not FAS entirely

10.1016/j.jfda.2017.05.001 7 BabarA.BabarM.ZubairH.ShahidA.RafiqueS.BanoM.et al (2024)